Philip Jonsson

8PUBLICATIONS
70CO-AUTHORS
Molecular targetsPredictive and prognostic markersCancer geneticsHaematological tumoursCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Aug 25, 2023
STX-478, a Mutant-Selective, Allosteric PI3Kα Inhibitor Spares Metabolic Dysfunction and Improves Therapeutic Response in PI3Kα-Mutant Xenografts.

Leonard Buckbinder, David J St Jean, Trang Tieu

|Mar 31, 2022
Anatomic position determines oncogenic specificity in melanoma.

Joshua M Weiss, Miranda V Hunter, Nelly M Cruz

|Nov 06, 2021
The context-specific role of germline pathogenicity in tumorigenesis.

Preethi Srinivasan, Chaitanya Bandlamudi, Philip Jonsson

|Dec 07, 2020
Clinical Outcome of Leiomyosarcomas With Somatic Alteration in Homologous Recombination Pathway Genes.

Evan Rosenbaum, Philip Jonsson, Kenneth Seier

|Jan 11, 2020
A Phase II Trial of Albumin-Bound Paclitaxel and Gemcitabine in Patients with Newly Diagnosed Stage IV Squamous Cell Lung Cancers.

Paul K Paik, Rachel K Kim, Linda Ahn

|Jul 03, 2019
Genomic Correlates of Disease Progression and Treatment Response in Prospectively Characterized Gliomas.

Philip Jonsson, Andrew L Lin, Robert J Young

Pageof 2

Frequent Collaborators

3 joint publications

Ahmet Zehir

2 joint publications

Alexander V Penson

2 joint publications

David B Solit

1 joint publications

Nusa Pristovsek